Roche: priority review in Duchenne myopathy
(CercleFinance.com) - Sarepta Therapeutics announced on Monday that the US FDA haz granted a priority review to its marketing application for SRP-9001, an experimental gene therapy for boys with Duchenne muscular dystrophy that the company is developing in collaboration with Roche.
In its statement, the US biotech said the health agency has set a target date of 29 May 2023 for the product's approval.
In December 2019, Roche entered into a partnership with Sarepta for the moxeparvovec delandistrogen gene therapy (SRP-9001) aimed at accelerating its availability outside the US.
Copyright (c) 2022 CercleFinance.com. All rights reserved.